Samo Pharmaceutical Raises Aminologics Stake to 41.79%, Named as Convertible Bond Call Option Holder

Samo Pharmaceutical raised its stake in Aminologics to 41.79%.

According to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART) on the 16th, Samo Pharmaceutical filed a report on its holdings of large blocks of shares and other securities in Aminologics on the 10th.

The filing showed that Samo Pharmaceutical and its specially related parties held 39,020,276 shares and other securities in Aminologics, for a 41.79% stake, up 5.21 percentage points from 36.58% in the previous report.

The number of shares held increased by 4,985,438 from 34,034,838 in the previous report.

However, the number of shares with voting rights remained unchanged from the previous report at 28,810,178, while the voting stake fell 0.11 percentage points, from 32.80% to 32.69%, due to an increase in the total number of shares issued.

The change in the stake resulted from the designation of holders to exercise call options on Aminologics’ fourth convertible bond.

On the 10th, Samo Pharmaceutical acquired a call option on 4,779,860 shares underlying the convertible bond. Specially related party Samo Pharmachem acquired options on 104,532 shares, while co-CEOs Jang-seok Oh and Seong-seok Oh each acquired options on 50,523 shares.

The acquisition price was 383 won per share, and Samo Pharmaceutical used 1.83123 billion won in funds on hand.

Samo Pharmachem used 400 million won in funds on hand, while co-CEOs Jang-seok Oh and Seong-seok Oh each used 19.35 million won in earned income to fund their acquisitions.

Samo Pharmaceutical, Aminologics’ largest shareholder, disclosed that its purpose for holding the shares was to influence management.